Open AccessImpact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience
Author(s) -
Giulia Rovesti,
Giulia Orsi,
Kalliopi Andrikou,
Caterina Vivaldi,
Giorgia Marisi,
Luca Faloppi,
Francesco Giuseppe Foschi,
Nicola Silvestris,
Irene Pecora,
Giuseppe Aprile,
Eleonora Molinaro,
Laura Riggi,
Paola Ulivi,
Matteo Canale,
Alessandro Cucchetti,
Emiliano Tamburini,
Giorgio Ercolani,
Lorenzo Fornaro,
Pietro Andreone,
Patrizia Zavattari,
Mario Scartozzi,
Stefano Cascinu,
Andrea CasadeiGardini
Publication year - 2019
Publication title -
gastrointestinal tumors
Language(s) - English
Resource type - Journals
eISSN - 2296-3766
pISSN - 2296-3774
DOI - 10.1159/000502714
Subject(s) - medicine , sorafenib , hepatocellular carcinoma , univariate analysis , gastroenterology , albumin , bilirubin , aspartate transaminase , alanine transaminase , multivariate analysis , portal vein thrombosis , thrombosis , alkaline phosphatase , biochemistry , chemistry , enzyme
Sorafenib has been established as the standard of care for patients with advanced hepatocellular carcinoma (HCC) since 2007 on the basis of two landmark trials (SHARP and Asia-Pacific). Ten years have passed since then and, despite much research in the field, still no validated real-life prognostic markers are available for HCC patients treated with this drug. Therefore, going through 10 years of research into sorafenib of several Italian Cancer Centers, we conducted a field-practice study aimed at identifying baseline clinical factors that could be significantly associated with overall survival (OS).